These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
965 related articles for article (PubMed ID: 34823373)
1. Trastuzumab deruxtecan for HER2+ advanced breast cancer. Lee J; Park YH Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373 [TBL] [Abstract][Full Text] [Related]
2. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. Indini A; Rijavec E; Grossi F Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310 [TBL] [Abstract][Full Text] [Related]
3. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I; N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192 [TBL] [Abstract][Full Text] [Related]
4. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study. Modi S Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665 [TBL] [Abstract][Full Text] [Related]
5. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan. Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422 [TBL] [Abstract][Full Text] [Related]
6. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France. Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172 [TBL] [Abstract][Full Text] [Related]
7. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA; N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644 [TBL] [Abstract][Full Text] [Related]
8. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Yamashita T; Sohn JH; Tokunaga E; Niikura N; Park YH; Lee KS; Chae YS; Xu B; Wang X; Im SA; Li W; Lu YS; Aguilar CO; Nishijima S; Nishiyama Y; Sugihara M; Modi S; Tsurutani J Breast Cancer; 2024 Sep; 31(5):858-868. PubMed ID: 38884900 [TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer. Bartsch R Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032 [TBL] [Abstract][Full Text] [Related]
10. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803 [TBL] [Abstract][Full Text] [Related]
11. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843 [TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer. Narayan P; Osgood CL; Singh H; Chiu HJ; Ricks TK; Chiu Yuen Chow E; Qiu J; Song P; Yu J; Namuswe F; Guiterrez-Lugo M; Hou S; Pierce WF; Goldberg KB; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA Clin Cancer Res; 2021 Aug; 27(16):4478-4485. PubMed ID: 33753456 [TBL] [Abstract][Full Text] [Related]
13. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer. Lee J; Kida K; Koh J; Liu H; Manyam GC; Gi YJ; Rampa DR; Multani AS; Wang J; Jayachandran G; Lee DW; Reuben JM; Sahin A; Huo L; Tripathy D; Im SA; Ueno NT J Exp Clin Cancer Res; 2024 Aug; 43(1):236. PubMed ID: 39164784 [TBL] [Abstract][Full Text] [Related]
14. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan. Ali A; Graff SL Curr Oncol Rep; 2024 Jan; 26(1):1-9. PubMed ID: 38091201 [TBL] [Abstract][Full Text] [Related]
15. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287 [TBL] [Abstract][Full Text] [Related]
16. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Saura C; Modi S; Krop I; Park YH; Kim SB; Tamura K; Iwata H; Tsurutani J; Sohn J; Mathias E; Liu Y; Cathcart J; Singh J; Yamashita T Ann Oncol; 2024 Mar; 35(3):302-307. PubMed ID: 38092229 [TBL] [Abstract][Full Text] [Related]
17. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer. Guarneri V; Passos Coelho JL; Duhoux FP; Egle D; García-Sáenz JÁ; Penault-Llorca F; Selander K; Wildiers H; Zaman K; Laeis P; Lucerna M; Pierga JY Future Oncol; 2024; 20(18):1237-1250. PubMed ID: 38592002 [TBL] [Abstract][Full Text] [Related]
18. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan. Schreiber AR; O'Bryant CL; Kabos P; Diamond JR Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278 [TBL] [Abstract][Full Text] [Related]